Real-World Impact of Bimekizumab on Disease Activity in axial spondyloarthritis patients including the EARLY subpopulation (EXPEDITE)

First published: 30/04/2025

Last updated: 03/06/2025

Study Ongoing

Administrative details

EU PAS number

EUPAS1000000519

Study ID

1000000519

DARWIN EU® study

No

Study countries

Austria

Belgium

European Union

France
Germany
Greece
Italy
Netherlands
Poland
Spain
Switzerland
United Kingdom

Study status

Ongoing

Contact details

Study institution contact

UCB Cares UCBCares.global@ucb.com

Study contact

UCBCares.global@ucb.com

Primary lead investigator

UCB Cares

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/04/2025

Actual: 09/04/2025

Study start date
Planned: 30/05/2025

Actual: 21/05/2025

Date of final study report
Planned: 25/10/2027

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

UCB Biopharma SRL

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

Internal study ID: SPA002

Methodological aspects

Study type

Study topic:

Human medicinal product

Study type:

Non-interventional study

Study drug and medical condition

Medicinal product name

BIMZELX

Study drug International non-proprietary name (INN) or common name

BIMEKIZUMAB

Anatomical Therapeutic Chemical (ATC) code

(L04AC21) bimekizumab

bimekizumab

Medical condition to be studied

Axial spondyloarthritis

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

No